SynAct Pharma AB (SE:SYNACT)
:SYNACT
Want to see SE:SYNACT full AI Analyst Report?
SYNACT Stock Chart & Stats
kr23.80
-kr0.24(-1.33%)
At close: 4:00 PM EST
kr23.80
-kr0.24(-1.33%)
Day’s Range― - ―
52-Week Rangekr7.05 - kr25.30
Previous CloseN/A
Volume43.49K
Average Volume (3M)214.83K
Market Cap
kr621.83M
Enterprise Valuekr501.49M
Total Cash (Recent Filing)kr68.89M
Total Debt (Recent Filing)kr1.54M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding53,330,242
10 Day Avg. Volume154,831
30 Day Avg. Volume214,829
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Therapeutic Pipeline (resomelagon/AP1189)A clear, durable R&D focus on immune-modulation and a lead oral candidate (resomelagon/AP1189) gives the company a concentrated development strategy. This specialization can improve trial design, regulatory positioning and partner interest over months, preserving long-term upside if clinical signals hold.
Very Low Financial LeverageMinimal debt reduces solvency risk and preserves strategic optionality for a clinical-stage biotech. Low leverage lowers fixed financial obligations, enabling management to prioritize R&D or pursue partnerships rather than servicing debt, a durable strength for the next several quarters.
Clear Commercialization Route Via Partnerships/out-licensingAs a pre-revenue biotech, having an established pathway—out-licensing and partnerships—offers a durable route to monetize assets without building commercial infrastructure. This model supports capital efficiency and aligns with common industry practice for small R&D-focused firms.
Bears Say
Persistent Negative Cash Flow And Heavy Cash BurnSustained negative operating and free cash flow indicate ongoing reliance on external financing to fund trials and operations. Heavy and steady cash burn pressures runway, increases dilution risk from future financings, and limits strategic flexibility over the medium term unless offset by partnerships or fundraising.
No Revenue And Widening Net LossesZero revenue with materially widening net losses reflects the classic pre-commercial biotech risk: escalating development costs without offsetting sales. This structural deficit heightens dependency on capital markets and partner deals, creating funding and continuity risk over the next several quarters.
Declining Shareholder Equity Signals Funding PressureA meaningful drop in equity reduces the balance sheet buffer and signals asset depletion or dilution. That decline implies the company may need near-term capital injections or deal activity to maintain operations, increasing execution risk and potential shareholder dilution over 2–6 months.
SynAct Pharma AB News
SYNACT FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was kr7.05 and its highest was kr25.30 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is kr621.83M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 62 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on May 27, 2026. The company reported -kr0.476 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.476.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -kr0.476 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.848%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in SE:SYNACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---